With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

As tools become more precise and non-invasive, doctors are able to diagnose and treat heart conditions with greater accuracy and efficiency.

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

The U.S. national coverage analysis for transcatheter tricuspid valve replacement drew support from cardiologists and device makers alike, but the Medical Device Manufacturers Association is urging ...

Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS is $0.59, expectations were $0.551. Mark Wilterding: [Starts Abruptly] ...

For some patients with atrial fibrillation (Afib, AF) and valvular heart disease (VHD), direct oral anticoagulants (DOACs) ...

JAMESTOWN — Two Sanford Health Fargo cardiology providers offer outreach services at Sanford Jamestown 2nd Ave. Clinic. Outreach services are offered on the second and fourth Wednesday of every month.

Edwards Lifesciences (NYSE:EW – Get Free Report) had its price objective upped by Morgan Stanley from $70.00 to $75.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an ...

Bleakley Financial Group LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 5.3% during the 4th ...

Long-time volunteer at Northwestern Medicine Delnor Hospital in Geneva celebrates procedure that saved her heart as hospital ...

UVM Medical Center is the only Vermont hospital offering Tricuspid Transcatheter Edge-to-Edge Repair (TEER) This new heart valve repair procedure brings leading-edge cardiac care closer to home for ...